In a report released on September 19, Joseph Vruwink from Robert W. Baird maintained a Hold rating on Certara (CERT – Research Report), with a price target of $17.00. The company’s shares closed yesterday at $14.30.
According to TipRanks, Vruwink is a 4-star analyst with an average return of 7.1% and a 60.98% success rate. Vruwink covers the Technology sector, focusing on stocks such as Autodesk, Veeva Systems, and Ansys.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Certara with a $19.29 average price target.
See the top stocks recommended by analysts >>
Based on Certara’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $90.45 million and a net profit of $4.71 million. In comparison, last year the company earned a revenue of $82.76 million and had a GAAP net loss of $589 thousand
Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CERT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Certara (CERT) Company Description:
Certara Inc accelerate medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides proven modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trial, accelerate regulatory approval and increase patient access to medicines.
Read More on CERT:
- Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software
- Certara to Participate in Upcoming Investor Conferences
- Certara Simcyp™ Group Awarded Two New Grants from US FDA
- Certara Simcyp group awarded two new grants by U.S. FDA
- Certara downgraded to Hold from Buy at Jefferies
